KRAS
Entity.
- Evidence
- 540 documents · 190 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 10 Nov 2026
- Measured
- 7% of mentions say something specific about it; the rest only name it
- As of
- 15 Nov 2026
Where this comes from
- Nature Medicine · 2026-11-10 · Next-generation KRAS G12C inhibitor improves survival in lung cancer (opens the source in a new tab)
- Nature Reviews Clinical Oncology · 2026-11-09 · Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC (opens the source in a new tab)
- Parasites Hosts Dis · 2026-11-06 · Toxoplasma gondii GRA16-induced apoptosis in KRAS-mutant colorectal cancer cells is linked to coordinated p53 and PP2A-B55 signaling. (opens the source in a new tab)
- Inside Precision Medicine · 2026-11-04 · New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC (opens the source in a new tab)
- Respirol Case Rep · 2026-11-02 · KRAS G12Y Causing a False-Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma. (opens the source in a new tab)
- The Medical News · 2026-10-31 · New strategy identified for overcoming resistance to KRAS-targeted cancer therapies (opens the source in a new tab)
- J Hematol Oncol · 2026-10-30 · KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. (opens the source in a new tab)
What is claimed about it
- Reported by two: Reported by two sources that did not copy each other.
- Single source: Reported by one source so far.
- Could not check: We could not count this claim's sources, so we do not say how well it is supported.
- PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling Could not check · first reported 13 Nov 2026
- Overcoming resistance to KRAS inhibition in KRAS/PIK3CA co-mutated colorectal cancer Could not check · first reported 12 Nov 2026
- [APPROVAL] FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer Single source · first reported 11 Nov 2026
- Next-generation KRAS G12C inhibitor improves survival in lung cancer Reported by two · first reported 10 Nov 2026
- Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC Could not check · first reported 9 Nov 2026